Laboratory:Akiruno
![](/js/ajax-loader.gif)
Laboratory:Akiruno
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
CK(CPK)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (10 days) |
2-4 | JSCC Standardization Compatibility Method |
M 62-287 F 45-163(U/L) |
CK-MB(CPK-MB)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (6 days) |
2-4 |
Immunoblocking - UV method UV method (Ultraviolet absorption spectrophotometry) |
MB 25 or less TOTAL M 62-287 F 45-163 (U/L) |
CK-MB(CPK-MB)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLIA CLIA (Chemiluminescent immunoassay) |
5.0 or less (ng/mL) |
|
![]() Serum 0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Agarose gel electrophoresis Electrophoresis |
BB 2 or less MB 6 or less MM 93-99 (%) |
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (14 days) |
2-4 | JSCC Standardization Compatibility Method | 10-40(U/L) |
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (14 days) |
2-4 | JSCC Standardization Compatibility Method | 5-40(U/L) |
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (3 days) |
2-4 | IFCC Standardization Compliance Act | 124-222(U/L) |
LD(LDH) Isozyme
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Agarose gel electrophoresis Electrophoresis |
LDH1 21-31 LDH2 28-35 LDH3 21-26 LDH4 7-14 LDH5 5-13(%) |
Alkaline phospathase (ALP), IFCC
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-4 | IFCC Standardization Compliance Act | 38-113(U/L) |
Bone alkaline phosphatase (BAP)
|
Serum
0.8 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
M3.7-20.9 Premenopausal women 2.9-14.5 Postmenopausal women 3.8-22.6 (μg/L) |
Placental alkaline phosphatase (PLAP)
|
Cerebrospinal fluid
0.5 |
A00 |
![]() (28 days) |
2-6 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
(pg/mL) | |
Alkaline phosphatase isoenzymes(IFCC)
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
Agarose gel electrophoresis Electrophoresis |
ALP1 0.0-5.3 ALP2 36.6-69.2 ALP3 25.2-54.2 ALP5 0.0-18.1 (%) |
γ-GT(γ-GTP)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-4 | JSCC Standardization Compatibility Method |
M 70 or less F 30 or less (U/L) |
Aldolase
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
UV Enzymatic method Enzyme method |
2.1-6.1(U/L) |
Cholinesterase (ChE)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-4 | JSCC Standardization Compatibility Method |
M 242-495 F 200-459 (U/L) |
Guanase
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Enzymatic method Enzyme method |
1.0 or less (U/L) |
Adenosine deaminase (ADA)
|
Serum
0.6 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Enzymatic method Enzyme method |
5.0-20.0(U/L) |
Leucine aminopeptidase (LAP)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-4 |
Enzymaticmethod(L-leucinep-nitroanilide) Enzyme method |
35-73(U/L) |
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | JSCC Standardization Compatibility Method | 37-125(U/L) |
Amylase (AMY)
|
Partial urine
0.5 |
U00 |
![]() |
2-4 |
Enzymatic method(Gal-G2-CNP substrate) Enzyme method |
65-700(U/L) | |
Amylase isoenzymes
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Agarose gel electrophoresis Electrophoresis |
TOTAL-S 36.0-84.3 TOTAL-P 15.7-64.0 (%) |
Amylase isoenzymes
|
Partial urine
0.5 |
U00 |
![]() |
2-4 |
Agarose gel electrophoresis Electrophoresis |
TOTAL-S 17.7-61.3 TOTAL-P 38.7-82.3 (%) |
|
Amylase, type P, quantitative
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 | JSCC Standardization Compatibility Method | 21-64(U/L) |
Lipase
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 | Synthetic substrate colorimetric method | 13-55(U/L) |
Trypsin
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Latex agglutination turbidimetry LA (Latex agglutination immunoassay) |
210-570(ng/mL) |
Pancreatic phospholipase A2 (pancreatic PLA2)
|
![]() Serum 0.3 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
RIA solid phase method IRMA (Immuno radio metric assay) |
130-400(ng/dL) |
Pancreatic phospholipase A2 (pancreatic PLA2)
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
2-4 |
RIA solid phase method IRMA (Immuno radio metric assay) |
130-400(ng/dL) |
Elastase 1
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Latex immunoturbidimetry | 300 or less (ng/dL) |
Granulocyte elastase in cervical mucus
|
Cervical mucus
|
VP6 |
![]() (1 month) |
2-4 | Latex agglutination immunoassay | 1.60 or less (μg/mL) | |
Tartrate resistant acid phosphatase (TRACP-5b)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme Immunoassay Assay) |
M 170-590 F(YAM) 120-420 (mU/dL) |
Lysozyme
|
Serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Nephelometry | 5.0-10.2(μg/mL) |
Lysozyme
|
Partial urine
0.4 |
U00 |
![]() |
2-4 | Nephelometry | Less than 0.1 (μg/mL) | |
Angiotensin I Converting enzyme (ACE)
|
Serum
0.7 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Kasahara method (Colorimetry) | 8.3-21.4(U/L) |
N-acetyl glucosaminidase (NAG)
|
Partial urine
0.5 |
U00 |
![]() |
2-4 |
Colorimetry Colorimetric method |
0.7-11.2(IU/L) | |
Pepsinogen
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
See below |
Matrix metalloproteinase 3 (MMP-3)
|
Serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | LTIA |
M 36.9-121 F 17.3-59.7 (ng/mL) |
Gastric cancer risk screening (ABC classification)〔LA〕
|
Serum
1.0 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
Latex agglutination turbidimetry CLEIA |
See below |
Gastric cancer risk screening (ABC classification), eradicated〔LA〕
|
Serum
1.0 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
Latex agglutination turbidimetry CLEIA |
See below |
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Protease method | 7 or less (U/L) |
|
Serum
0.8 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
EIA CLEIA |
|
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 | DCAP-P substrate method | 14.4 or less (U/L) |
|
Serum
0.8 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
EIA CLEIA |
See below |